|
1
|
Luo CY, Li N, Lu B, Cai J, Lu M, Zhang YH,
Chen HD and Dai M: Global and regional trends in incidence and
mortality of female breast cancer and associated factors at
national level in 2000 to 2019. Chin Med J (Engl). September
28–2021.(Epub ahead of print). doi: 10.1097/CM9.0000000000001814.
View Article : Google Scholar
|
|
2
|
Waks AG and Winer EP: Breast cancer
treatment: A review. JAMA. 321:288–300. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oh DY and Bang YJ: HER2-targeted
therapies-a role beyond breast cancer. Nat Rev Clin Oncol.
17:33–48. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Andre F, Ciruelos E, Rubovszky G, Campone
M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, et al:
Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced
breast cancer. N Engl J Med. 380:1929–1940. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hortobagyi GN, Chen D, Piccart M, Rugo HS,
Burris HA III, Pritchard KI, Campone M, Noguchi S, Perez AT, Deleu
I, et al: Correlative analysis of genetic alterations and
everolimus benefit in hormone receptor-positive, human epidermal
growth factor receptor 2-negative advanced breast cancer: Results
from BOLERO-2. J Clin Oncol. 34:419–426. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gong X, Litchfield LM, Webster Y, Chio LC,
Wong SS, Stewart TR, Dowless M, Dempsey J, Zeng Y, Torres R, et al:
Genomic aberrations that activate D-type cyclins are associated
with enhanced sensitivity to the CDK4 and CDK6 inhibitor
abemaciclib. Cancer Cell. 32:761–776.e6. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ellis MJ, Ding L, Shen D, Luo J, Suman VJ,
Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, et al:
Whole-genome analysis informs breast cancer response to aromatase
inhibition. Nature. 486:353–360. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cancer Genome Atlas Network. Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pham TT, Angus SP and Johnson GL: MAP3K1:
Genomic alterations in cancer and function in promoting cell
survival or apoptosis. Genes Cancer. 4:419–426. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pereira B, Chin SF, Rueda OM, Vollan HK,
Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ,
et al: The somatic mutation profiles of 2,433 breast cancers
refines their genomic and transcriptomic landscapes. Nat Commun.
7:114792016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hammond ME, Hayes DF, Dowsett M, Allred
DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS,
Hayes M, et al: American Society of Clinical Oncology/College Of
American Pathologists guideline recommendations for
immunohistochemical testing of estrogen and progesterone receptors
in breast cancer. J Clin Oncol. 28:2784–2795. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al: Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American society of
clinical oncology/college of American pathologists clinical
practice guideline update. J Clin Oncol. 31:3997–4013. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li H and Durbin R: Fast and accurate short
read alignment with Burrows-Wheeler transform. Bioinformatics.
25:1754–1760. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sahraeian SME, Mohiyuddin M, Sebra R,
Tilgner H, Afshar PT, Au KF, Bani Asadi N, Gerstein MB, Wong WH,
Snyder MP, et al: Gaining comprehensive biological insight into the
transcriptome by performing a broad-spectrum RNA-seq analysis. Nat
Commun. 8:592017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang K, Li M and Hakonarson H: ANNOVAR:
Functional annotation of genetic variants from high-throughput
sequencing data. Nucleic Acids Res. 38:e1642010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cingolani P, Platts A, Wang le L, Coon M,
Nguyen T, Wang L, Land SJ, Lu X and Ruden DM: A program for
annotating and predicting the effects of single nucleotide
polymorphisms, SnpEff: SNPs in the genome of Drosophila
melanogaster strain w1118; iso-2; iso-3. Fly (Austin). 6:80–92.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Newman AM, Bratman SV, Stehr H, Lee LJ,
Liu CL, Diehn M and Alizadeh AA: FACTERA: A practical method for
the discovery of genomic rearrangements at breakpoint resolution.
Bioinformatics. 30:3390–3393. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen X, Zhang G, Chen B, Wang Y, Guo L,
Cao L, Ren C, Wen L and Liao N: Association between histone lysine
methyltransferase KMT2C mutation and clinicopathological factors in
breast cancer. Biomed Pharmacother. 116:1089972019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang G, Wang Y, Chen B, Guo L, Cao L, Ren
C, Wen L, Li K, Jia M, Li C, et al: Characterization of frequently
mutated cancer genes in Chinese breast tumors: A comparison of
Chinese and TCGA cohorts. Ann Transl Med. 7:1792019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Stephens PJ, Tarpey PS, Davies H, Van Loo
P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell
GR, et al: The landscape of cancer genes and mutational processes
in breast cancer. Nature. 486:400–404. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jezequel P, Campone M, Gouraud W,
Guerin-Charbonnel C, Leux C, Ricolleau G and Campion L:
bc-GenExMiner: An easy-to-use online platform for gene prognostic
analyses in breast cancer. Breast Cancer Res Treat. 131:765–775.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jezequel P, Frenel JS, Campion L,
Guerin-Charbonnel C, Gouraud W, Ricolleau G and Campone M:
bc-GenExMiner 3.0: New mining module computes breast cancer gene
expression correlation analyses. Database (Oxford).
2013:bas0602013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sorlie T, Tibshirani R, Parker J, Hastie
T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et
al: Repeated observation of breast tumor subtypes in independent
gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hu Z, Fan C, Oh DS, Marron JS, He X,
Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, et al: The
molecular portraits of breast tumors are conserved across
microarray platforms. BMC Genomics. 7:962006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Desmedt C, Haibe-Kains B, Wirapati P,
Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M and
Sotiriou C: Biological processes associated with breast cancer
clinical outcome depend on the molecular subtypes. Clin Cancer Res.
14:5158–5165. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wirapati P, Sotiriou C, Kunkel S, Farmer
P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag
T, Schütz F, et al: Meta-analysis of gene expression profiles in
breast cancer: Toward a unified understanding of breast cancer
subtyping and prognosis signatures. Breast Cancer Res. 10:R652008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Parker JS, Mullins M, Cheang MC, Leung S,
Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, et al:
Supervised risk predictor of breast cancer based on intrinsic
subtypes. J Clin Oncol. 27:1160–1167. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Haibe-Kains B, Desmedt C, Rothe F, Piccart
M, Sotiriou C and Bontempi G: A fuzzy gene expression-based
computational approach improves breast cancer prognostication.
Genome Biol. 11:R182010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kwong A, Cheuk IW, Shin VY, Ho CY, Au CH,
Ho DN, Wong EY, Yu SW, Chen J, Chan KK, et al: Somatic mutation
profiling in BRCA-negative breast and ovarian cancer patients by
multigene panel sequencing. Am J Cancer Res. 10:2919–2932.
2020.PubMed/NCBI
|
|
31
|
Griffith OL, Spies NC, Anurag M, Griffith
M, Luo J, Tu D, Yeo B, Kunisaki J, Miller CA, Krysiak K, et al: The
prognostic effects of somatic mutations in ER-positive breast
cancer. Nat Commun. 9:34762018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ellis MJ, Suman VJ, Hoog J, Goncalves R,
Sanati S, Creighton CJ, DeSchryver K, Crouch E, Brink A, Watson M,
et al: Ki67 proliferation index as a tool for chemotherapy
decisions during and after neoadjuvant aromatase inhibitor
treatment of breast cancer: Results from the American college of
surgeons oncology group Z1031 trial (Alliance). J Clin Oncol.
35:1061–1069. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Carene D, Tran-Dien A, Lemonnier J, Dalenc
F, Levy C, Pierga JY, Jacot W, Canon JL, Richon C, Lacroix L, et
al: Association between FGFR1 copy numbers, MAP3K1 mutations, and
survival in axillary node-positive, hormone receptor-positive, and
HER2-negative early breast cancer in the PACS04 and METABRIC
studies. Breast Cancer Res Treat. 179:387–401. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Koelblinger P, Dornbierer J and Dummer R:
A review of binimetinib for the treatment of mutant cutaneous
melanoma. Future Oncol. 13:1755–1766. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sweeny DJ, Li W, Clough J, Bhamidipati S,
Singh R, Park G, Baluom M, Grossbard E and Lau DT: Metabolism of
fostamatinib, the oral methylene phosphate prodrug of the spleen
tyrosine kinase inhibitor R406 in humans: Contribution of hepatic
and gut bacterial processes to the overall biotransformation. Drug
Metab Dispos. 38:1166–1176. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Haasbach E, Hartmayer C and Planz O:
Combination of MEK inhibitors and oseltamivir leads to synergistic
antiviral effects after influenza A virus infection in vitro.
Antiviral Res. 98:319–324. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yan M, Dai T, Deak JC, Kyriakis JM, Zon
LI, Woodgett JR and Templeton DJ: Activation of stress-activated
protein kinase by MEKK1 phosphorylation of its activator SEK1.
Nature. 372:798–800. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fanger GR, Johnson NL and Johnson GL: MEK
kinases are regulated by EGF and selectively interact with
Rac/Cdc42. EMBO J. 16:4961–4972. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wagner EF and Nebreda AR: Signal
integration by JNK and p38 MAPK pathways in cancer development. Nat
Rev Cancer. 9:537–549. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xue Z, Vis DJ, Bruna A, Sustic T, van
Wageningen S, Batra AS, Rueda OM, Bosdriesz E, Caldas C, Wessels
LFA and Bernards R: MAP3K1 and MAP2K4 mutations are associated with
sensitivity to MEK inhibitors in multiple cancer models. Cell Res.
28:719–729. 2018. View Article : Google Scholar : PubMed/NCBI
|
